Live Breaking News & Updates on Prnewswire Glenmark Pharmaceuticals Ltd|Page 1

Stay updated with breaking news from Prnewswire glenmark pharmaceuticals ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - 'Ichnos Glenmark Innovation'

(This story has not been edited by THE WEEK and is auto-generated from a PTI ....

New York , United States , Glenn Saldanha , Cyril Konto , Biosimilars Companies , Prnewswire Glenmark Pharmaceuticals Ltd , Ichnos Sciences Inc , Glenmark Pharmaceuticals Ltd , Linkedin Glenmark Pharmaceuticals , Ichnos Sciences , Ichnos Glenmark Innovation , New York City , Managing Director , Glenmark Pharmaceuticals , Glenmark Innovation , Asset Pipeline , Astria Therapeutics , Pharmaceutical Sales , Biosimilars Companies Ranked , Great Place To Work , Green House Gas , Science Based Target , Ichnos Glenmark ,

Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24

Pti: Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24 ....

South Africa , United States , Glenmark Pharma , Glenn Saldanha , Glenmark Europe , Linkedin Glenmark Pharmaceuticals , Glenmark Pharmaceuticals Limited , Biosimilars Companies , Indian Pharmaceuticals , Glenmark Life Sciences , Glenmark Life Sciences Ltd , Glenmark Pharmaceuticals , Prnewswire Glenmark Pharmaceuticals Ltd , Glenmark Pharmaceuticals Ltd , Glenmark Life Sciences Limited , Source Name , India Business , North America Business , Continuing Operations , Managing Director , Nirma Limited , Pharmaceuticals Limited , Pharmaceutical Sales , Biosimilars Companies Ranked , Great Place To Work , Green House Gas ,

Glenmarks Ryaltris®- innovative single nasal spray, ready to market in Russia

Glenmarks Ryaltris®- innovative single nasal spray, ready to market in Russia
MUMBAI, India, Feb. 22, 2021 /PRNewswire/ Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S A, received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris® Nasal Spray - a novel fixed-dose combination nasal spray.
This paves the way for commercialization of Ryaltris® in Russia which is expected to be made available to patients in the country in Q1 FY 2021-22.
Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg) is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris® relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes. ....

United States , South Africa , Saudi Arabia , Russian Federation , Csaba Kantor , Glenmarks Ryaltris , Seqirus Pty , Drug Administration , Glenmark Pharmaceuticals , Prnewswire Glenmark Pharmaceuticals Ltd , Menarini Group , Ministry Of Health The Russian Federation , Glenmark Pharmaceuticals Ltd , China Co , Nasal Spray , Senior Vice President , Dow Jones Sustainability Index , Corporate Sustainability , Exclusive Licensing , Regulatory Authorities , Grand Pharmaceutical , ஒன்றுபட்டது மாநிலங்களில் , சவுதி அரேபியா , ரஷ்ய கூட்டமைப்பு , க்ளேண்மர்க் மருந்துகள் , அமைச்சகம் ஆஃப் ஆரோக்கியம் தி ரஷ்ய கூட்டமைப்பு ,

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing
MUMBAI, India, Dec 23, 2020 /PRNewswire/ Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. ....

South Africa , L Vivs Ka Oblast , Yu Han , Saudi Arabia General , Saudi Arabia , South Korea , Sachin Gupta , Pio Mei , Seqirus Pty , Menarini Group , Glenmark Pharmaceuticals , Research Development , Yuhan Corporation , Prnewswire Glenmark Pharmaceuticals Ltd , European Union , Latam Glenmark Pharmaceuticals , Menarini Pharmaceutical Group , Hikma Pharmaceuticals , Glenmark Pharmaceuticals Ltd , China Co , Exclusive Licensing Agreement , While Glenmark , Executive Vice President , Business Head , Middle East , General Manager Menarini ,